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Summary
Background Reslizumab 3 mg/kg administered intravenously is approved for the treatment of severe eosinophilic 
asthma. We assessed the safety and efficacy of subcutaneous reslizumab 110 mg in two trials in patients with 
uncontrolled severe asthma and increased blood eosinophils. The aim was to establish whether subcutaneous 
reslizumab 110 mg can reduce exacerbation rates in these patients (study 1) or reduce maintenance oral corticosteroid 
dose in patients with corticosteroid-dependent asthma (study 2).
Methods Both studies were randomised, double-blind, placebo-controlled, phase 3 studies. Entry criteria for study 1 
were uncontrolled severe asthma, two or more asthma exacerbations in the previous year, a blood eosinophil count of 
300 cells per µL or more (including no more than 30% patients with an eosinophil count <400 cells/µL), and at least 
a medium dose of inhaled corticosteroids with one or more additional asthma controllers. Patients in study 2 had 
severe asthma, a blood eosinophil count of 300 cells per µL or more, daily maintenance oral corticosteroid (prednisone 
5–40 mg, or equivalent), and high-dose inhaled corticosteroids plus another controller. Patients were randomly 
assigned (1:1) to subcutaneous reslizumab (110 mg) or placebo once every 4 weeks for 52 weeks in study 1 and 
24 weeks in study 2. Patients and investigators were masked to treatment assignment. Primary efficacy outcomes 
were frequency of exacerbations during 52 weeks in study 1 and categorised percentage reduction in daily oral 
corticosteroid dose from baseline to weeks 20–24 in study 2. Primary efficacy analyses were by intention to treat, and 
safety analyses included all patients who received at least one dose of study treatment. These studies are registered 
with ClinicalTrials.gov, NCT02452190 (study 1) and NCT02501629 (study 2).
Findings Between Aug 12, 2015, and Jan 31, 2018, 468 patients in study 1 were randomly assigned to placebo (n=232) 
or subcutaneous reslizumab (n=236), and 177 in study 2 to placebo (n=89) or subcutaneous reslizumab (n=88). In 
study 1, we found no significant difference in the exacerbation rate between reslizumab and placebo in the intention-
to-treat population (rate ratio 0·79, 95% CI 0·56–1·12; p=0·19). Subcutaneous reslizumab reduced exacerbation 
frequency compared with placebo in the subgroup of patients with blood eosinophil counts of 400 cells per μL or 
more (0·64, 95% CI 0·43–0·95). Greater reductions in annual exacerbation risk (p=0·0035) and longer time to first 
exacerbation were observed for patients with higher trough serum reslizumab concentrations. In study 2, we found 
no difference between placebo and fixed-dose subcutaneous reslizumab in categorised percentage reduction in daily 
oral corticosteroid dose (odds ratio for a lower category of oral corticosteroid use in the reslizumab group vs the 
placebo group, 1·23, 95% CI 0·70–2·16; p=0·47). The frequency of adverse events and serious adverse events with 
reslizumab were similar to those with placebo in both studies.
Interpretation Fixed-dose (110 mg) subcutaneous reslizumab was not effective in reducing exacerbation frequency in 
patients with uncontrolled asthma and increased blood eosinophils (≥300 cells/µL), or in reducing the daily 
maintenance oral corticosteroid dose in patients with oral corticosteroid-dependent severe eosinophilic asthma. Higher 
exposures than those observed with 110 mg subcutaneous reslizumab are required to achieve maximal efficacy.
Funding Teva Branded Pharmaceutical Products R&D.
Copyright © 2020 Elsevier Ltd. All rights reserved.
Introduction
Eosinophils have a key role in the promotion and 
maintenance of airway inflammation, airway wall 
thickening, fibrosis, and angiogenesis in patients with 
eosinophilic asthma.1 Baseline counts of blood and 
sputum eosinophils can be markers of the severity of 
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asthmatic symptoms and independent risk factors 
for future asthma exacerbations in patients with 
symptomatic asthma.2–4
Maintenance and activation of eosinophils is dependent 
on interleukin-5 (IL5), the prototypical eosinophil viability-
enhancing factor.5 Several monoclonal antibodies that 
target the IL5 pathway are approved as add-on maintenance 
treatment for inadequately controlled severe eosinophilic 
asthma.6–8 Reslizumab is an IgG4-κ humanised anti-IL5 
monoclonal antibody that is administered as intravenous 
infusion at a recommended weight-based dose of 3 mg/kg, 
once every 4 weeks.8 Efficacy and safety of intravenous 
reslizumab have been shown in five phase 3 clinical 
trials.9–12 Weight-based dosing of intravenous reslizumab 
significantly reduced the risk of asthma exacerbations 
and improved asthma control, lung function, and quality 
of life in patients with inadequately controlled asthma, 
peripheral blood eosinophil counts of 400 cells per μL 
or more, and a history of asthma exacerbations.9 
The availability of subcutaneous administration as an 
alternative to intravenous administration could increase 
the accessibility of reslizumab treatment, reduce time and 
resource requirements associated with intravenous 
infusion,13,14 and simplify administration.
We did two phase 3 clinical trials, which were designed 
to investigate the safety and efficacy of reslizumab given as 
a fixed-dose (110 mg) subcutaneous injection once every 
4 weeks in patients with uncontrolled asthma and 
increased blood eosinophils. Study 1 was an asthma 
exacerbation study that investigated the effect of fixed-dose 
subcutaneous reslizumab on the rate of clinical asthma 
exacerbations, and study 2 was a corticosteroid-sparing 
study that investigated the potential oral corticosteroid-
sparing properties of fixed-dose subcutaneous reslizumab 
in patients with oral corticosteroid-dependent severe 
asthma.
Methods
Study design
Both studies were randomised, double-blind, placebo-
controlled, parallel-group, phase 3 studies. Full details of 
the study methods are provided in the appendix (p 3). 
Study 1 consisted of a 2-week screening period, a 
minimum 3-week run-in period, a 52-week treatment 
Research in context
Evidence before this study
We searched PubMed for publications from inception to 
May 3, 2019, using the terms “anti-interleukin-5 antibodies” or 
“reslizumab” and “asthma” for clinical trials investigating anti-
interleukin 5 (IL5) biologic drugs in patients with severe 
eosinophilic asthma. In two phase 3 trials, weight-based 
dosing of intravenous reslizumab (3 mg/kg) reduced clinical 
asthma exacerbation frequency and improved asthma control, 
lung function, and quality of life. In other reslizumab studies, 
improvement in lung function was found with intravenous 
reslizumab (0·3 mg/kg and 3 mg/kg); the greatest 
improvement in lung function with the higher dose was 
observed in patients with a blood eosinophil count of 400 cells 
per µL or more. Clinical trials of other drugs that target the IL5 
pathway were also identified. Studies have shown that 
intravenous or subcutaneous anti-IL5 or anti-IL5 receptor 
drugs reduce asthma exacerbations and improve lung 
function, asthma control, and quality of life, and reduce 
maintenance oral corticosteroid dose in patients with severe 
eosinophilic asthma.
Added value of this study
To our knowledge, these are the first published studies that have 
assessed the safety and efficacy of low-dose reslizumab 
administered as a fixed-dose subcutaneous injection for the 
treatment of severe eosinophilic asthma. The results of these 
studies suggest that the lower dose and lower systemic 
reslizumab concentrations associated with fixed-dose 
subcutaneous reslizumab, compared with intravenous 
reslizumab, might not be sufficient to provide robust reductions 
in exacerbation frequency in patients with uncontrolled asthma 
and increased blood eosinophil counts (≥300 cells/µL), or to 
reduce daily maintenance oral corticosteroid dose in patients 
with oral corticosteroid-dependent severe asthma. Results 
indicate that the exposure–response relationships and systemic 
reslizumab concentration thresholds differ between the 
endpoints of asthma exacerbations and lung function. Greater 
effect on asthma exacerbations was observed in the prespecified 
subgroup of patients with a high blood eosinophil count 
(≥400 cells/µL), which matched the population in the phase 3 
studies of intravenous reslizumab. Regional differences in 
background asthma exacerbation rate during the study period 
were also observed.
Implications of all the available evidence
A complete analysis of the effect of body weight on systemic 
concentrations and a clear understanding of the exposure–
response relationships for primary and key secondary asthma 
endpoints, before initiation of phase 3 studies, would be 
beneficial to support optimal future study design for biologic 
drugs in severe asthma. Our results support further assessment of 
higher doses of weight-based subcutaneous reslizumab. Baseline 
blood eosinophil counts are a marker of patients who are more 
responsive to therapies targeting the IL5 pathway, reconfirming 
the importance of defining the eosinophilic phenotype; however, 
treatment-induced suppression of blood eosinophils with anti-
IL5 therapy is not sufficient to ensure robust clinical efficacy. 
A reduction in blood eosinophil counts with treatment is a 
surrogate biomarker, which might not fully reflect changes in 
eosinophilic airway inflammation in patients with severe asthma. 
Regional differences in asthma exacerbation rates have been 
observed and should be considered during future study design.
See Online for appendix
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period, and a 12-week follow-up. Study 2 had a 2-week 
screening period, followed by an oral corticosteroid dose 
optimisation period of up to 10 weeks, a minimum 2-week 
run-in period, a 24-week treatment period, and an 8-week 
follow-up. For study 1, at least one patient was randomly 
assigned at each of 155 study sites in 20 countries: USA 
(43 sites), Ukraine (19), Hungary (16), Germany (11), 
Argentina (10), Russia (8), Israel (8), Poland (6), 
Romania (5), South Africa (5), Japan (4), Mexico (3), 
Belgium (3), Czech Republic (3), Turkey (3), Canada (2), 
Spain (2), New Zealand (2), France (1), and Australia (1). 
For study 2, at least one patient was randomly assigned at 
each of 78 study sites in 17 countries: Ukraine (15), 
the USA (9), Germany (7), Poland (7), Argentina (6), 
Russia (6), Mexico (5), Israel (5), Spain (3), Australia (2), 
South Korea (2), France (2), the Netherlands (2), 
Belgium (2), Hungary (2), Czech Republic (2), and Italy (1).
The subcutaneous reslizumab fixed dose of 110 mg was 
selected on the basis of clinical data from an intravenous 
reslizumab phase 3, 16-week, FEV1 study in patients with 
eosinophilic asthma,11 in which improvements in lung 
function and asthma control and reductions in blood 
eosinophil counts were obtained with intravenous doses 
of 0·3 mg/kg and 3 mg/kg. Although data on asthma 
exacerbations were not collected during the treatment 
period, the similar magnitude of effect on FEV1 between 
the 0·3 mg/kg and 3 mg/kg doses suggested that the 
doses would also have similar effects on asthma 
exacerbation frequency. A 110 mg subcutaneous dose 
approximates to a 1 mg/kg intravenous dose for the 
average 70 kg patient, when adjusting for subcutaneous 
bioavailability, and was therefore expected to result in 
clinical efficacy in most patients. The 1 mL volume and 
presentation in a pre-filled syringe would be convenient 
for subcutaneous administration.
Both studies were done in accordance with the 
Declaration of Helsinki and the International Conference 
on Harmonisation guidelines for Good Clinical Practice. 
All study documents and procedures were approved by 
the appropriate Institutional Review Board or Ethics 
Committee at each study site. All patients provided 
written informed consent before study participation.
Study 1
Participants
We included participants aged 12 years or older with a 
diagnosis of asthma, an Asthma Control Questionnaire-6 
(ACQ-6) score of at least 1·5 at screening, two or more 
asthma exacerbations requiring the use of systemic 
corticosteroids in the past year, a blood eosinophil count 
of 300 cells per µL or more during screening, and 
an FEV1 reversibility of 12% or more to inhaled short-
acting β agonist at screening or documentation within 
12 months of signing informed consent. Patients were 
receiving at least a medium dose (>250 μg/day fluticasone 
or equivalent) of inhaled corticosteroids for at least 
3 months with at least one additional asthma controller 
for at least 3 months (or documented failure of a second 
controller in the past 12 months). For patients using 
inhaled corticosteroid and long-acting β agonist (LABA) 
combinations, the mid-strength approved maintenance 
dose in the local country met this inhaled corticosteroid 
criterion. Oral corticosteroid use (prednisone 10 mg or 
less daily, or equivalent) was allowed. Full inclusion and 
exclusion criteria are summarised in the appendix (p 3).
Randomisation and masking
Patients were randomly assigned (1:1) to receive sub-
cutaneous reslizumab (110 mg) or placebo. Participants 
were assigned using an interactive web response 
system (IWRS). Randomisation was stratified by age 
(12 to <18 years and ≥18 years) and blood eosinophil count 
at screening (300 to <400 cells/μL and ≥400 cells/μL). A 
maximum of 30% of patients enrolled could have a blood 
eosinophil count of between 300 cells per μL and less than 
400 cells per μL; when this threshold was met, only 
patients with blood eosinophil counts of 400 cells per μL 
or more were enrolled. The inclusion criterion of a 
baseline blood eosinophil count of 300 cells per µL or 
more was based on the available published literature on 
biologic drugs for treating severe asthma at the time of 
study design.15–17 Anti-IL5 therapies have been shown to 
reduce asthma exacerbations in patients with baseline 
blood eosinophil counts of 150 cells per µL or more15 or 
300 cells per µL or more.16,17 However, data for 3 mg/kg 
intravenous reslizumab suggested robust effects across 
multiple asthma endpoints in patients with baseline blood 
eosinophil counts of 400 cells per µL or more; therefore, 
we restricted the enrolment of patients with blood 
eosinophils between 300 cells per μL and less than 
400 cells per μL to 30%. Patients and investigators were 
masked to treatment assignment. The sponsor’s personnel 
involved in the study were also masked to the study drug 
identity, until the database was locked for analysis and the 
treatment assignment was revealed.
Procedures
Eligible patients received either one 1·0 mL sub-
cutaneous injection containing 110 mg reslizumab, or 
one 1·0 mL subcutaneous injection containing sterile 
placebo solution, once every 4 weeks. Reslizumab and 
placebo were provided as matching, clear solutions. 
Treatment continued for 52 weeks, with the last dose 
administered at week 48 followed by an end-of-treatment 
visit at week 52. Patients maintained their inhaled 
asthma controller regimen without change throughout 
screening, optimisation, run-in, treatment, and follow-
up periods (appendix p 3).
Outcomes
The primary efficacy outcome was the frequency of 
clinical asthma exacerbations per patient during the 
52-week treatment period. A clinical asthma exacerbation 
was defined as a clinically judged deterioration in asthma 
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control resulting in at least one of the following: use 
of systemic corticosteroids (oral or injection), at least a 
doubling from a stable maintenance oral corticosteroid 
dose for 3 days or more, or an asthma-specific hospital 
admission or emergency department visit. A pre-specified, 
powered subgroup analysis assessed the frequency of 
clinical asthma exacerbations per patient during the 
52-week treatment period in patients who had baseline 
blood eosinophil counts of 400 cells per μL or more.
Secondary outcomes included lung function,  as assessed 
by measurement of change from baseline in pre-
bronchodilator FEV1; patient-reported outcomes (ie, 
change in ACQ-6 and AQLQ+12 scores at 52 weeks), 
safety; and immunogenicity (appendix p 13). Blood 
eosinophil counts at specified timepoints during the 
treatment period and follow-up visit were assessed (at 
12 weeks after end of treatment); the highest value from 
screening to predose on the day of randomisation was 
used as baseline.
Serum reslizumab concentrations were determined 
from blood samples collected at baseline; before study 
drug administration at weeks 4, 8, 12, 16, 20, 32, 48, 
and 52; and at early withdrawal or at the follow-up visit. 
An additional sample was taken at long-term follow-up 
(appendix p 5).
Study 2
Participants
We included patients aged 12 years or older with a 
diagnosis of asthma, an FEV1 reversibility of 12% or more 
after inhaled reliever medication at screening, or a 
historical FEV1 reversibility or a positive methacholine 
challenge within 24 months, a blood eosinophil count of 
300 cells per µL or more within the past 12 months while 
on at least a medium total daily dose of inhaled cortico-
steroids, during screening, during oral corticosteroid 
optimisation, or at the week –2 visit (appendix p 7). 
Patients required an average daily maintenance dose 
of oral corticosteroid for asthma (prednisone 5–40 mg, 
or equivalent) during the 3 months before screening. 
Patients also required high-dose inhaled corticosteroids 
(≥880 μg of inhaled fluticasone propionate, or equivalent) 
plus another controller for at least 6 months before 
screening. For a fixed-dose preparation of inhaled cortico-
steroid plus LABA, the highest labelled dose in the local 
country satisfied this criterion. For patients aged 12 to 
less than 18 years, at least a medium-dose inhaled 
corticosteroid plus another controller was required. The 
dose and regimen needed to have been stable for at least 
30 days. Full inclusion and exclusion criteria are 
summarised in the appendix (p 8).
Randomisation and masking
Patients were randomly assigned (1:1) to receive 
subcutaneous reslizumab (110 mg) or placebo. The 
randomisation list and treatment were assigned to the 
relevant treatment groups using an IWRS. Randomisation 
Asthma exacerbation study 
(study 1)
Oral corticosteroid-sparing 
study (study 2)
Placebo 
(n=230)*
Subcutaneous
reslizumab 
(n=234)*
Placebo 
(n=89)
Subcutaneous 
reslizumab 
(n=88)
Age, years 44·8 (17·7) 46·9 (17·6) 53·1 (12·0) 55·5 (12·7)
Sex, n (%)
Men 102 (44%) 90 (38%) 32 (36%) 28 (32%)
Women 128 (56%) 144 (62%) 57 (64%) 60 (68%)
Weight, kg
Mean (SD) 76·9 (18·3) 78·3 (19·4) 82·7 (18·9) 79·6 (21·4)
Median (IQR) 75·0 (23.6) 77·5 (25.2) 82·0 (20.7) 75·6 (26.2)
BMI, kg/m² 27·4 (6·1) 28·3 (6·2) 29·9 (6·3) 29·4 (8·0)
FEV1 reversibility, % 24·6% (21·3) 22·8% (17·1) 24·6% (20·5) 26·0% (25·9)
Pre-bronchodilator FEV1, L 2·1 (0·9) 2·0 (0·8) 1·7 (0·7) 1·6 (0·7)
FEV1, % predicted 65·0% (19·7) 64·4% (18·3) 58·7% (19·8) 55·2% (16·7)
ACQ-6 score 2·6 (0·8) 2·6 (0·8) 2·4 (1·2) 2·3 (1·1)
AQLQ score 4·4 (1·0) 4·3 (1·0) 4·4 (1·2) 4·4 (1·1)
Blood eosinophil count, cells/µL† 737 (484) 787 (538) 521 (491) 479 (388)
Eosinophil count
<300 cells/µL 0 1 (<1%) 33 (37%) 28 (32%)
≥300 to <400 cells/µL 42 (18%) 48 (21%) 13 (15%) 19 (22%)
≥400 cells/µL 188 (82%) 185 (79%) 43 (48%) 41 (47%)
Phadiatop test
Positive 154 (67%) 159 (68%) 47 (53%) 47 (53%)
Missing 12 (5%) 4 (2%) 3 (3%) 1 (1%)
Former smoker 28 (12%) 31 (13%) 13 (15%) 12 (14%)
Age at asthma onset, years 27·5 (19·2) 29·0 (19·9) 32·9 (17·9) 32·8 (17·7)
Time since diagnosis, years 17·5 (13·5) 18·0 (14·0) 20·1 (14·2) 22·3 (16·0)
Asthma exacerbations requiring 
systemic corticosteroids in the 
past 12 months
2·3 (0·8) 2·4 (1·0) 1·85 (1·2) 2·1 (1·6)
Inhaled corticosteroid 229 (>99%)‡ 232 (>99%)‡ 89 (100%) 88 (100%)
High-dose§ 98 (43%) 99 (42%) 70 (79%)¶ 70 (80%)¶
Medium-dose§ 122 (53%) 128 (55%) 17 (19%) 18 (20%)
Long-acting β agonist 218 (95%) 224 (96%) 84 (94%) 87 (99%)
Oral corticosteroid 15 (7%) 15 (6%) 89 (100%) 88 (100%)
Aspirin sensitivity|| 23 (10%) 26 (11%) 7 (8%) 5 (6%)
Chronic rhinosinusitis with nasal 
polyps||
38 (17%) 37 (16%) 13 (15%) 10 (11%)
Data are mean (SD), or n (%), unless otherwise indicated. ACQ-6=Asthma Control Questionnaire-6. AQLQ=Asthma 
Quality of Life Questionnaire. BMI=body-mass index. ITT=intention-to-treat. *Two patients in the placebo group and 
two patients in the reslizumab group were excluded from the ITT analysis. One site was terminated because of 
recurrent irregularities in data collection and recording. The patients who were randomly assigned at this site were 
excluded from the ITT analysis set. †Stated baseline eosinophil count reflected the highest value from measurements 
during screening, run-in, and pre-dose day of randomisation. ‡Three patients presented as not using inhaled 
corticosteroids at baseline; two (one in each treatment group) were using inhaled corticosteroids at baseline but were 
counted as non-inhaled corticosteroid users. Of these two patients, the first was using budesonide with formoterol 
fumarate, which was not coded as an inhaled corticosteroid, and the second was using beclomethasone with 
formoterol, which was not counted as a baseline medication because of missing dates (the dates were confirmed to 
be unknown, but were >3 months before screening). The third patient (in the reslizumab group) was not using 
inhaled corticosteroid at baseline. §High-dose was defined as >500 µg/day fluticasone or equivalent and medium-
dose as >250 to ≤500 µg/day fluticasone or equivalent. ¶In regions where the inhaled corticosteroid dose in the 
highest labelled fixed-dose preparation of inhaled corticosteroid and long-acting β agonist was <500 µg/day 
fluticasone or equivalent, patients receiving the highest labelled dose in that region were deemed to satisfy the 
inclusion criterion. ||Self-reported.
Table 1: Demographics and baseline clinical characteristics of the intention-to-treat population in 
studies 1 and 2
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was stratified by optimised average daily oral corticosteroid 
dose (>10 mg or ≤10 mg) and age (12 to <18 years and 
≥18 years) at baseline. Patients and investigators were 
masked to treatment assignment. The sponsor’s personnel 
involved in the study were also masked to the study drug 
identity, until the database was locked for analysis and the 
treatment assignment was revealed.
Procedures
To achieve the patient’s minimal effective oral 
corticosteroid requirement (appendix p 9), the oral 
corticosteroid dose was reduced at weekly intervals for 
up to 10 weeks or until asthma signs and symptoms 
worsened (minimum 1 day in optimisation). Oral 
corticosteroid optimisation was considered finished when 
patients had worsening of asthma signs and symptoms, 
or if patients optimised to an oral corticosteroid dose of 
less than 5 mg without worsening of asthma signs and 
symptoms.
Patients whose minimal effective oral corticosteroid 
dose remained in the range 5–40 mg prednisone daily at 
the end of optimisation could advance to run-in, after 
which patients received either one 1·0 mL subcutaneous 
injection containing 110 mg reslizumab, or matched 
placebo, once every 4 weeks. Treatment continued for 
24 weeks, with the last dose administered at week 20, 
followed by an end-of-treatment visit at week 24. Patients 
maintained an inhaled asthma controller regimen without 
change throughout the study. The treatment period 
consisted of a stable-dose induction period of 4 weeks, 
followed by an oral corticosteroid reduction period. 
During oral corticosteroid reduction, the oral corticosteroid 
dose was reduced in accordance with the protocol, based 
on meeting asthma stability criteria at scheduled monthly 
clinic visits during weeks 5–20 (appendix p 9).
Outcomes
The primary efficacy outcome was categorised percentage 
reduction in daily oral corticosteroid dose compared with 
baseline (end of the optimisation phase) during weeks 
20–24: 90 to 100%; 75 to <90%; 50 to <75%; >0 to <50%; 
no decrease in oral corticosteroid dose or loss of asthma 
control during weeks 20–24; or treatment discontinuation 
(withdrawal of treatment). Loss of asthma control was 
defined as FEV1 less than 80% of baseline at week 24, 
clinically significant worsening in ACQ-6 score (increase 
in score ≥0·5 points) at week 24 compared with baseline, 
or clinical asthma exacerbation during weeks 20–24. 
Patients with missing data or loss of asthma control with 
reduced oral corticosteroid dose were included in the 
category reflecting the lowest efficacy.
Secondary outcomes included additional assessments 
of oral corticosteroid dose reduction, clinical asthma 
exacerbations, safety, and immunogenicity (appendix p 
10). The assessment of blood eosinophil counts was 
similar to that in study 1; the highest value from 
screening to week –2 was used as baseline.
Serum reslizumab concentrations were determined 
from blood samples collected at baseline; before study 
drug administration at weeks 4, 8, 12, 16, 20, and 24; and 
at early withdrawal or at the follow-up visit. An additional 
sample was taken at long-term follow-up (appendix p 7).
Statistical analysis
The primary efficacy analyses used the intention-to-treat 
(ITT) population of each study, which included all 
randomly assigned patients. Analyses were also done in 
the per-protocol populations, defined as all patients from 
the ITT population without major protocol violations. 
(Figure 1 continues on next page)
1159 patients assessed for eligibility
691 ineligible
 30 withdrawal by patient
 578 inclusion criteria not met
 57 exclusion criteria met
 8 lost to follow up
 18 other
468 enrolled
232 assigned to placebo
230 included in intention-to-treat analysis
208 included in per-protocol analysis
2 excluded from intention-to-treat 
 population (study site terminated 
 because of irregularities in data
 collection and recording)
22 excluded from per-protocol analysis*
 4 inclusion criteria not met
 5 exclusion criteria met
 1 non-compliance to study medication
 14 excluded concomitant medication 
  or treatment
 2 other
33 discontinued treatment
 19 withdrawal by patient
 2 adverse event
 4 lost to follow-up
 3 lack of efficacy
 3 other
 1 non-compliance with study drug
 1 pregnancy
468 randomised
236 assigned to subcutaneous reslizumab
234 included in intention-to-treat analysis
213 included in per-protocol analysis
2 excluded from intention-to-treat 
 population (study site terminated 
 because of irregularities in data
 collection and recording)
21 excluded from per-protocol analysis*
 2 excluded from intention-to-treat
 3 inclusion criteria not met
 5 exclusion criteria met
 1 GCP guidelines
 14 excluded concomitant medication 
  or treatment
22 discontinued treatment
 1 death
 11 withdrawal by patient
 5 adverse event
 3 lost to follow-up
 1 lack of efficacy
 1 other
A
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Safety was assessed in the safety population of each 
study, which included all patients who received at least 
one dose of study treatment.
Simulation studies were done with SAS (version 9.4) to 
assess the statistical powers for analysing the frequency of 
exacerbations using a negative binomial model in study 1, 
and the power analysis software PASS (version 13.0.7) was 
used for sample size estimation in study 2. The model 
assumptions involved in the calculations are described in 
detail in the appendix (p 11). In brief, power calculations 
for study 1 were based on a mean of 2·9 exacerbations per 
patient per year in the placebo group, a dispersion 
parameter of 1·2 in the negative Binomial model for both 
treatment groups, and treatment effect of 45% between 
reslizumab and placebo. On the basis of these 
assumptions, 225 patients per group would provide more 
than 90% power to detect a significant treatment effect of 
reslizumab versus placebo in the reduction of exacerbation 
rate. For study 2, a sample size of 76 patients per treatment 
group was chosen to provide 90% power to detect a 
significant effect of reslizumab over placebo on the 
probability for a higher categorical reduction of oral 
corticosteroid dose using a proportional odds model. This 
was based on the assumption in the placebo group that 
after 24 weeks of treatment 10·9% of patients have 
90–100% reduction, 7·9% have 75 to <90% reduction, 
14·8% have 50 to <75% reduction, 10·8% have 0 to <50% 
reduction, and 55·6% have no reduction, have loss of 
asthma control, or discontinue; also assuming odds ratio 
(OR) based on a proportional odds model of 2·63.
For both studies, a fixed-sequence, multiple-testing 
procedure was implemented to test the primary and 
secondary outcomes while controlling the overall type I 
error rate at 0·05. Primary and secondary outcomes were 
tested sequentially and hierarchically. If the resulting 
two-sided p value from the primary comparison was less 
than 0·05, then the next comparison was interpreted 
inferentially. No multiplicity adjustments were made for 
other efficacy and exploratory analyses. All statistical 
analyses were done using SAS (versions 9.1.3 and 9.2).
The frequency of clinical asthma exacerbations was 
analysed with a generalised linear model for data from 
the negative binomial regression model. Treatment 
group, randomisation stratification factors (age and 
baseline blood eosinophil count for study 1; age and 
oral corticosteroid dose for study 2), and number of 
exacerbations in the previous year were model factors. 
Logarithm of follow-up duration minus the summed 
duration of exacerbations was an offset variable. Adjusted 
clinical asthma exacerbation rates, rate ratios (RR), and 
95% CIs were calculated. In study 1, multiple imputation 
was used for missing data in the primary analysis model. 
Sensitivity analyses were done without imputed data. 
Because of convergence issues with the primary analysis 
Figure 1: Trial profiles for studies 1 and 2
GCP=good clinical practice. *A patient might have had multiple reasons for exclusion from the per-protocol analysis.
B
77 included in per-protocol analysis 78 included in per-protocol analysis
273 patients assessed for eligibility
93 ineligible
 5 withdrawal from study
 66 inclusion criteria not met
 11 exclusion criteria met
 1 lost to follow-up
 10 other
180 enrolled
89 assigned to placebo
89 included in intention-to-treat analysis
12 excluded from per-protocol analysis*
 6 inclusion criteria not met
 5 primary objective variable
 2 excluded concomitant medication 
  or treatment
6 discontinued treatment
 1 adverse event
 2 withdrawal by patient
 1 lack of efficacy
 2 discontinued treatment due to
 technical issues
177 randomised
88 assigned to subcutaneous reslizumab
3 not randomised
88 included in intention-to-treat analysis
10 excluded from per-protocol analysis*
 2 inclusion criteria not met
 1 exclusion criteria met
 6 primary objective variable
 1 non-compliance to study medication
4 discontinued treatment
 1 death
 2 withdrawal by patient
 1 lack of efficacy
Overall population Eosinophil count
300–<400 cells/μL
Eosinophil count
≥400 cells/μL
0
Ad
ju
st
ed
 a
nn
ua
l f
re
qu
en
cy
 o
f 
cli
ni
ca
l a
st
hm
a 
ex
ac
er
ba
tio
ns
0·2
0·4
0·6
0·8
1·0
n=234
0·41
0·52
RR 0·79
(95% CI 0·562–1·124)
p=0·19
RR 1·78
(95% CI 0·690–4·569)
RR 0·64
(95% CI 0·430–0·945)
0·75
0·42
0·56
0·87
n=230 n=48 n=42 n=185 n=188
Subcutaneous reslizumab
Placebo
Figure 2: Adjusted frequency of clinical asthma exacerbations during 
52 weeks in the intention-to-treat population and in subgroups of patients 
based on baseline eosinophil counts in study 1
For this analysis, the offset variable is calculated as the logarithm of treatment 
duration minus the summed duration of exacerbations during the treatment 
period. RR=rate ratio.
Articles
www.thelancet.com/respiratory   Published online February 14, 2020   https://doi.org/10.1016/S2213-2600(19)30372-8 7
model in study 1, a post-hoc data-driven analysis of 
the effects of subcutaneous reslizumab was done 
(appendix p 6).
Change from baseline in pre-bronchodilator FEV1 was 
analysed with a mixed-model repeated measures model, 
with fixed effects for treatment, visit, treatment-by-visit 
interaction, sex, age group, and blood eosinophil group; 
height and baseline value as covariates; and patient as a 
random effect. Unstructured covariance was assumed 
for the repeated measures.
In study 2, categorised percentage reduction in total 
daily oral corticosteroid dose at weeks 20–24 was analysed 
with a proportional odds model including factors for 
treatment group and randomisation strata (age group 
and oral corticosteroid dose). Baseline oral corticosteroid 
dose and duration of oral corticosteroid use before study 
entry were also included as covariates. ORs, 95% CIs, 
and p values were calculated. A prespecified sensitivity 
analysis was done with the per-protocol population.
Statistical methods for the secondary efficacy and 
safety outcomes in both studies are provided in the 
appendix (pp 6, 11). Prespecified subgroups for the 
subgroup analyses are detailed in the appendix (pp 7, 12). 
Model results were only reported if there were 15 patients 
or more contributing to the analysis in each treatment 
group; otherwise, descriptive statistics were generated. 
Eosinophil count (300 to <400 cells/μL and ≥400 cells/μL) 
at baseline was a prespecified stratification factor for 
study 1, which recruited a sufficient proportion of patients 
with eosinophil counts of 400 cells per μL or more (a 
minimum of 70% of the study population, per protocol). 
This subgroup analysis was prespecified for the primary 
analysis and selected secondary efficacy analyses.
The exposure–response analysis was assessed a 
posteriori using SAS (version 9.4). We identified the 
relationship between individual reslizumab trough 
concentrations (Ctrough) and clinical asthma exacerbation 
rate in study 1 using visual graphical analysis with a 
regression coefficient. Individual Ctrough was based on the 
aggregate information for each individual using a model 
that accounted for the differences in time after the most 
recent dose and provided a single concentration measure 
for use in the exposure–response analysis. Patients in the 
placebo group were assumed to have concentrations of 
0 µg/mL. The underlying hazard for a clinical asthma 
exacerbation was explored with Kaplan-Meier survival 
curves of the time to first clinical asthma exacerbation, 
stratified by tertiles of reslizumab Ctrough in study 1. 
These studies are registered with ClinicalTrials.gov, 
NCT02452190 (study 1) and NCT02501629 (study 2).
Role of the funding source
Three authors of the report (DAM, MG, and RV) are 
employees of Teva Branded Pharmaceutical Products 
R&D, the study funder, and two (JM and LH) are former 
employees of the study funder. Employees of the study 
funder had roles in the design of the study, data 
collection, data analysis, data interpretation, and writing 
of the report. All authors had full access to all of the data 
outputs, and the corresponding author had final 
responsibility for the decision to submit for publication.
Results 
Between Aug 12, 2015, and Oct 10, 2016, 1159 patients 
were recruited in study 1, of whom 468 patients were 
enrolled and randomly assigned to receive placebo (n=232 
[50%]) or subcutaneous reslizumab (n=236 [50%]). The 
last visit of the last patient occurred on Jan 31, 2018. 
Between Sept 22, 2015, and Dec 12, 2016, 273 patients 
were recruited in study 2, of whom 180 were enrolled and 
177 were randomly assigned to receive placebo (n=89) or 
subcutaneous reslizumab 110 mg (n=88). The last visit of 
the last patient occurred on Dec 4, 2017. Within each study, 
demographic and baseline disease characteristics were 
ITT population Eosinophil count 300 to <400 cells/μL Eosinophil count ≥400 cells/μL
Placebo 
(n=230)
Subcutaneous 
reslizumab 
(n=234)
Placebo 
(n=42)
Subcutaneous 
reslizumab 
(n=48)
Placebo 
(n=188)
Subcutaneous 
reslizumab 
(n=185)
Adjusted CAEs excluding exacerbation duration from the offset* 0·52 0·41 0·42 0·75 0·87 0·56
RR (95% CI) for reslizumab vs placebo ·· 0·79 (0·56 to 1·12) ·· 1·78 (0·69 to 4·57) ·· 0·64 (0·43 to 0·95)
p value ·· 0·19 ·· .. ·· ..
Change in pre-bronchodilator FEV1 at 52 weeks, L, LSM (SE)† 0·23 (0·040) 0·37 (0·039)  0·25 (0.093) 0·38 (0.092) 0·26 (0.042) 0·41 (0.041)
Absolute increase (95% CI) vs placebo ·· 0·14 (0·057 to 0·23) ·· 0·13 (–0·053 to 0·31) ·· 0·15 (0·054 to 0·25)
Change in ACQ-6 at 52 weeks, LSM (SE)‡ –1·14 (0·080) –1·22 (0·078) –1·36 (0.19) –1·27 (0.19) –1·05 (0.084) –1·18 (0.081)
Absolute change (95% CI) vs placebo ·· –0·09 (–0·27 to 0·10) ·· 0·09 (–0·31 to 0·48) ·· –0·12 (–0·32 to 0·083)
Change in AQLQ+12 at 52 weeks, LSM (SE)*§ 1·06 (0·089) 1·14 (0·087) 1·25 (0·20) 1·30 (0·20) 1·02 (0.093) 1·11 (0.091)
Absolute increase (95% CI) vs placebo ·· 0·08 (–0·11 to 0·27) ·· 0·05 (–0·38 to 0·49) ·· 0·08 (–0·14 to 0·30)
ACQ-6=Asthma Control Questionnaire-6. AQLQ+12=Asthma Quality of Life Questionnaire for patients aged ≥12 years. CAE=clinical asthma exacerbation. ITT=intention-to-treat. LSM=least squares mean. 
RR=rate ratio. *For this analysis, the offset variable was calculated as the logarithm of treatment duration minus the summed duration of exacerbations during the treatment period. †Minimal clinically important 
difference was a change of 0·1 L. ‡Minimal clinically important difference was change in score of –0·5. §Minimal clinically important difference was change in score of 0·5. 
Table 2: Primary and key secondary efficacy outcomes in study 1
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well balanced across the two treatment groups (table 1). 
The demographic and baseline disease characteristics for 
patients in study 1 by baseline eosinophil subgroup are 
shown in the appendix (p 13). Trial profiles are shown in 
figure 1. In study 1, 59 (13%) of 468 patients discontinued 
study treatment (35 [15%] of 232 in the placebo group and 
24 [10%] of 236 in the reslizumab group). Seven patients 
were reported as lost to follow-up (four in the placebo 
group and three in the reslizumab group). In study 2, 
10 (6%) of 177 patients discontinued study treatment 
(six [7%] of 89 in the placebo group and four [5%] of 88 in 
the reslizumab group).
In study 1, the frequency of clinical asthma 
exacerbations did not differ significantly over 52 weeks 
between fixed-dose subcutaneous reslizumab and 
placebo in the ITT population (RR 0·79, 95% CI 
0·56–1·12; p=0·19; figure 2, table 2). As the analysis of 
the primary efficacy outcome did not meet the criteria for 
statistical significance, subsequent efficacy outcomes 
were not interpreted inferentially (figure 2, table 2). 
Fixed-dose subcutaneous reslizumab reduced clinical 
asthma exacerbation frequency compared with placebo 
in the prespecified subgroup of patients with eosinophil 
counts of 400 cells per μL or more (0·64, 95% CI 
0·43–0·95), but not in those with eosinophil counts of 
between 300 cells per μL and less than 400 cells per μL 
(figure 2, table 2).
In the prespecified subgroups, patients enrolled in 
Europe had the smallest treatment effect, and adults 
aged 65 years or older had a slightly greater reduction in 
the frequency of clinical asthma exacerbations with fixed-
dose subcutaneous reslizumab compared with placebo 
(appendix p 14). The findings of the other prespecified 
subgroup analyses were consistent with those of the 
primary analysis (appendix p 14). In a post-hoc analysis 
of patients enrolled in eastern Europe (110 [47%] in the 
reslizumab group and 99 [43%] in the placebo group), the 
treatment effect was smaller than for the overall results 
from all of Europe (data not shown), apparently driven by 
a low frequency of clinical asthma exacerbations in the 
placebo group (mean of 0·3 [standard error 0·06] 
exacerbations during the treatment period). Results in 
the per-protocol sensitivity analysis were similar to those 
in the primary ITT analysis (data not shown).
In the ITT population, the change from baseline in pre-
bronchodilator FEV1 at week 52 was larger with fixed-dose 
subcutaneous reslizumab compared with placebo 
(figure 3, table 2). Improvements in pre-bronchodilator 
FEV1 with fixed-dose subcutaneous reslizumab were seen 
rapidly (ie, at 2 weeks) and were maintained throughout 
52 weeks (figure 3). Increases from baseline at week 52 for 
pre-bronchodilator FEV1 were larger for fixed-dose 
subcutaneous reslizumab than placebo in both the 
prespecified eosinophil subgroups (figure 3, table 2).
Overall ACQ-6 scores decreased from baseline to 
week 52 in both treatment groups in the ITT population; 
however, ACQ-6 scores were lower for fixed-dose 
Figure 3: Change in pre-bronchodilator FEV1 from baseline at each visit by treatment group in study 1
(A) The intention-to-treat population, (B) patients with baseline eosinophil counts of 300 to <400 cells per μL, and 
(C) patients with baseline eosinophil counts of ≥400 cells per μL. Least squares mean and SE are given for the 
change from baseline in FEV1 at each clinic visit between the first dose of study drug and the end-of-treatment visit 
for completed patients, and between the first dose of study drug and 4 weeks after the last dose of study drug for 
patients who discontinued treatment early. Inferential statistics are from a mixed-model repeated measures 
model with fixed effects for treatment, visit, treatment-by-visit interaction, sex, age group, and blood eosinophil 
group; height and baseline value as covariates; and patient as a random effect. Unstructured covariance was 
assumed for the repeated measures.
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subcutaneous reslizumab at all postbaseline timepoints 
(appendix p 15). The least squares mean change in ACQ-6 
score from baseline to week 52 did not differ for fixed-dose 
subcutaneous reslizumab and placebo (table 2, appendix 
p 15). ACQ-6 findings for the prespecified eosinophil 
subgroups are provided in table 2. Increases in Asthma 
Quality of Life Questionnaire for 12 years and older 
(AQLQ+12) were observed with both treatment groups. 
Changes from baseline in AQLQ+12 scores at 52 weeks 
were similar for subcutaneous reslizumab and placebo in 
the ITT population (table 2) and prespecified eosinophil 
subgroups (table 2). Treatment differences between fixed-
dose subcutaneous reslizumab and placebo did not 
approach the minimal clinically important difference in 
the ITT population or in either of the prespecified 
eosinophil subgroups.
We found no meaningful difference between results of 
the other prespecified subgroup analyses (appendix p 7) 
and those of the ITT analysis for the key secondary 
outcomes (data not shown). Results of the other secondary 
efficacy analyses (Asthma symptom assessment at week 
52 [based on a daily asthma control diary]; percentage of 
asthma control days at week 52 from baseline; change 
from baseline in St George’s Respiratory Questionnaire 
score at week 32; probability of having a clinical asthma 
exacerbation by week 52; frequency of clinical asthma 
exacerbations requiring hospitalisation or emergency 
department visit; and frequency of moderate asthma 
exacerbations, defined as exacerbations requiring 
additional asthma controlling medication that was not a 
systemic corticosteroid, and that did not result in an 
asthma-specific hospitalisation or emergency department 
visit during the 52-week treatment period) are presented 
in the appendix (p 7).
In study 2, we found no statistically significant 
difference between reslizumab and placebo across the 
five-level categorised percentage reductions in daily oral 
corticosteroid dose during weeks 20–24 compared with 
baseline (end of the optimisation phase; OR 1·23, 95% CI 
0·70–2·16; p=0·47; table 3). Results in the per-protocol 
sensitivity analysis were similar to those of the primary 
ITT analysis (appendix p 19). No notable differences 
between fixed-dose subcutaneous reslizumab and 
placebo were observed for patients in any of the 
prespecified subgroup analyses (appendix p 19).
Placebo 
(n=89)
Subcutaneous
reslizumab 
(n=88)
Categorised percentage oral corticosteroid dose reduction (5-level 
response) at weeks 20–24*
90 to 100% 20 (22%) 18 (20%)
75 to <90% 4 (4%) 8 (9%)
50 to <75% 8 (9%) 13 (15%)
>0 to <50% 9 (10%) 7 (8%)
No decrease† 48 (54%) 42 (48%)
Reslizumab vs placebo ·· 1·23 (0·70–2·16)
p value ·· 0·47
Categorised oral corticosteroid dose reduction (responder analyses) at 
weeks 20–24
At least 50% reduction from baseline 32 (36%) 39 (44%)
Reslizumab vs placebo ·· 1·45 (0·79–2·68)
Oral corticosteroid dose ≤5 mg 34 (38%) 37 (42%)
Reslizumab vs placebo ·· 1·19 (0·63–2·23)
Oral corticosteroid dose 0 mg 20 (22%) 18 (20%)
Reslizumab vs placebo ·· 0·82 (0·37–1·82)
At least 5 mg reduction from baseline 31 (35%) 36 (41%)
Reslizumab vs placebo ·· 1·36 (0·72–2·56)
Data are n (%) or OR (95% CI), unless otherwise indicated. OR=odds ratio. *All 
data were included; missing data were included as non-responders. †No decrease 
in oral corticosteroid dose, loss of baseline asthma control during weeks 20–24, or 
discontinuation from study drug.
Table 3: Oral corticosteroid outcomes in the intention-to-treat 
population in study 2
Figure 4: Change in blood eosinophil count from baseline at each visit in the intention-to-treat population in 
studies 1 and 2
Data are least squares mean and SE for (A) study 1 and (B) study 2. Follow-up was at 12 weeks after the 52-week 
treatment period in study 1, and at 8 weeks after the 24-week treatment period in study 2.
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Because the analysis of the primary efficacy outcome 
did not meet the criteria for statistical significance, 
secondary efficacy outcomes were not interpreted 
inferentially. Both treatment groups showed decreases in 
oral corticosteroid dose over the treatment period 
(table 3). We found no significant differences in the 
secondary efficacy analyses for the ITT population 
(appendix p 20) or subgroup analyses of secondary 
outcomes (data not shown).
In both studies, blood eosinophil counts decreased in 
both treatment groups between baseline and first visit 
and remained below baseline until the end of treatment. 
Eosinophil counts began to rise towards baseline at the 
follow-up visits. Mean blood eosinophil counts among 
patients receiving fixed-dose subcutaneous reslizumab 
were lower than those of patients receiving placebo 
at the first post-baseline visit and all subsequent 
timepoints (figure 4). In study 1, the mean change from 
baseline to week 52 was –0·205 × 10⁹/L (SD 0·4709) in 
the placebo group and –0·698 × 10⁹/L (0·5356) in the 
fixed-dose subcutaneous reslizumab group. In study 2, 
the mean change from baseline to week 24 was 
–0·144 × 10⁹/L (0·5040) in the placebo group and 
–0·385 × 10⁹/L (0·3570) in the fixed-dose subcutaneous 
reslizumab group.
Baseline and reslizumab Ctrough for both studies are 
reported in the appendix (pp 24–25). Patient body weight 
and Ctrough were correlated and higher reslizumab Ctrough 
was observed in patients with a lower body weight 
(appendix p 26).
In study 1, higher Ctrough values were associated with a 
lower annual frequency of clinical asthma exacerbations. 
A regression fit indicated a significant correlation 
between clinical asthma exacerbation frequency and 
individual Ctrough values (p=0·0035; figure 5).
The time to first clinical asthma exacerbation analysis 
indicated the greatest treatment effect (longest time to 
first clinical asthma exacerbation) in patients with Ctrough 
in the upper tertile (the group with the highest Ctrough 
exposures). The Ctrough exposures were 4·90 µg/mL or less 
for the lowest tertile, between 4·90 and less than 
7·46 µg/mL for the middle tertile, and more than 
7·46 µg/mL for the upper tertile, with the placebo group 
assumed to have an exposure of 0 µg/mL. The median 
Ctrough was 5·99 µg/mL (IQR 4·52–8·20; figure 6).
Within each study, the incidence of adverse events (AEs) 
was similar across the two treatment groups (table 4). The 
most common AEs (≥5% in either group) in study 1 were 
(viral or unspecified) upper respiratory tract infection, 
allergic rhinitis, acute sinusitis, headache, bronchitis, 
injection-site erythema, and asthma; and in study 2 were 
viral upper respiratory tract infection, asthma, bronchitis, 
headache, influenza, injection-site pain, and allergic 
rhinitis. Injection-site reactions occurred in 19 (8%) of 
231 patients in the placebo group and 27 (11%) of 
237 patients in the reslizumab group in study 1, and in 
two (2%) of 89 patients in the placebo group and five (6%) 
of 88 patients in the reslizumab group in study 2
The most common serious AEs (SAEs) across both 
studies with reslizumab were asthma (table 4). In study 1, 
SAEs were assessed by investigators as being not related 
to study treatment, with the exception of two patients in 
the reslizumab group (respiratory infection and 
pulmonary embolism in one patient, and benign tracheal 
and bronchial tumour in another patient). In study 2, no 
SAEs during the study were assessed as being related to 
treatment.
One death occurred during the treatment period across 
both studies. In study 2, an adult man died 7 days after the 
first dose of reslizumab. The death was reported as sudden 
death and no autopsy was done. The death was considered 
by the investigator to be unrelated to treatment. In study 1, 
one patient from the reslizumab group died from hospital-
acquired pneumonia and septicaemia during the follow-
up period, more than 1 month after the last subcutaneous 
reslizumab dose. This event was not considered to be 
related to the study drug.
One (<1%) patient in the placebo group and five (2%) 
patients in the fixed-dose subcutaneous reslizumab 
group discontinued treatment due to AEs in study 1. 
These AEs were of a diverse nature and, apart from 
benign tracheal and bronchial tumour and increased 
liver enzymes, were considered by the investigator to be 
not related to the study drug. In study 2, one patient in 
the placebo group discontinued treatment because of an 
AE.
No hypersensitivity AEs were deemed by the 
investigator to be causally related to reslizumab (appendix 
p 27).
Positive anti-drug antibody response in the reslizumab 
group was noted in 17 (7·2%) of 236 patients in study 1, 
and 11 (13%) of 88 patients in study 2. Titres of the 
anti-drug antibody-positive responses were generally low. 
All titres were transient in study 2 and most were 
Figure 5: Relationship between trough serum concentration of reslizumab and annual frequency of clinical 
asthma exacerbations in study 1
Ctrough=reslizumab trough concentration.
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transient in study 1 (most being single observations that 
resolved). We found no association between positive anti-
drug antibody response and efficacy or safety outcomes 
(data not shown). All anti-drug antibody-positive samples 
were analysed using the neutralising antibody assay and 
none was identified as having neutralising activity.
Discussion
In study 1, 52 weeks of add-on therapy with fixed-dose 
(110 mg) subcutaneous reslizumab did not result in 
a significantly different frequency of clinical asthma 
exacerbations, compared with placebo, in the ITT 
population; however, our findings indicate that res-
lizumab treatment was associated with a reduced risk of 
exacerbations in the prespecified subgroup of patients 
with eosinophil counts of 400 cells per μL or more. This 
subgroup was fully powered a priori and aligned with the 
study population in phase 3 trials of intravenous 
reslizumab.9 The results of the secondary efficacy analyses 
suggest a clinically significant improvement in lung 
function, as measured by FEV1, which was greater with 
reslizumab compared with placebo at all timepoints. 
Improvements in lung function were already seen by the 
first measured timepoint, at week 2, and were sustained 
over 52 weeks. We observed no effect of subcutaneous 
reslizumab on the annual rate of clinical asthma 
exacerbations in the prespecified subgroup of patients 
with an eosinophil count between 300 cells per µL and 
less than 400 cells per µL, in whom eosinophilia is less 
likely to be the major contributor to asthma severity; 
however, the sample size was too small to draw 
conclusions for an event-driven endpoint such as asthma 
exacerbations, as indicated by the high variability in this 
subgroup. The finding of improvements in clinical 
asthma exacerbation frequency and lung function with 
reslizumab in the prespecified subgroup of patients with 
high blood eosinophil counts suggests that blood 
eosinophil counts are a marker of responsiveness to 
therapies targeting the IL5 pathway,15,16 reconfirming the 
importance of defining the eosinophilic phenotype. 
Indeed, the findings for reslizumab in the two 
Figure 6: Kaplan-Meier survival curves for time to first clinical asthma exacerbation by tertiles of trough serum concentration of reslizumab in study 1
One patient in the placebo group received reslizumab and was excluded from the analysis. Ctrough=trough reslizumab concentration.
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Injection-site erythema 7 (3%) 13 (5%) 0 0
Injection-site pain 9 (4%) 10 (4%) 1 (1%) 4 (5%)
Asthma 21 (9%) 12 (5%) 6 (7%) 8 (9%)
Influenza 7 (3%) 10 (4%) 2 (2%) 4 (5%)
Hypertension 10 (4%) 6 (3%) 5 (6%) 1 (1%)
Any serious adverse events 19 (8%) 19 (8%) 4 (4%) 10 (11%)
Serious adverse events occurring in ≥2% of patients by preferred term
Asthma 5 (2%) 4 (2%) 2 (2%) 3 (3%)
Pneumonia 4 (2%) 2 (<1%) 0 1 (1%)
Cholecystolithiasis 4 (2%) 0 0 0
Adverse events leading to discontinuation 
from treatment
1 (<1%) 5 (2%) 1 (1%) 0
Deaths 0 0 0 1 (1%)
Data are n (%), based on the number of patients who had at least one adverse event of a particular classification. One 
patient in the placebo group received reslizumab.
Table 4: Adverse events during treatment by treatment group (safety population) in both studies
Articles
12 www.thelancet.com/respiratory   Published online February 14, 2020   https://doi.org/10.1016/S2213-2600(19)30372-8
prespecified eosinophil subgroups suggest that a baseline 
threshold of 400 cells per µL or more is an indicator of the 
efficacy of reslizumab. These results are consistent with 
the findings of our intravenous reslizumab study,9 which 
showed no further reduction in the frequency of clinical 
asthma exacerbations with increasing baseline eosinophil 
counts higher than 400 cells per µL.
The primary outcome findings from study 1 for 
subcutaneous reslizumab differ from those of previous 
phase 3 studies of weight-based dosing of intravenous 
reslizumab,9 which showed a 50–59% reduction in clinical 
asthma exacerbations over 52 weeks, and these differences 
are probably at least partly due to differences in drug 
exposure between the two studies. The dose administered 
with subcutaneous reslizumab 110 mg approximates to a 
1 mg/kg intravenous dose for the average 70 kg patient 
when accounting for bioavailability. Therefore, 110 mg 
administered subcutaneously was a substantially lower 
dose than that obtained with 3 mg/kg weight-based dosing 
for all observed body weights when accounting for 
bioavailability. For example, the median body weight in 
study 1 was 76 kg, and patients of this weight would have 
received a reslizumab dose of approximately 228 mg with 
3 mg/kg weight-based dosing compared with the 110 mg 
subcutaneous dose used in these studies. The 110 mg 
subcutaneous dose was selected on the basis of previous 
clinical data for intravenous reslizumab at a lower dose of 
0·3 mg/kg in a 16-week FEV1 study,11 and at the time the 
effect of exposures at lower doses on clinical asthma 
exacerbation rates was not as clearly understood. 
Additionally, for a monoclonal antibody with a soluble 
target such as IL5, for which clearance of the drug is 
influenced by body weight, a single fixed dose most likely 
results in a gradient of concentrations based on the 
distribution of body weights across a population. Indeed, 
our correlative data showed reduced drug exposure to 
fixed-dose reslizumab in patients with higher body 
weight. By contrast, weight-based dosing of intravenous 
reslizumab resulted in consistent exposures across body 
weights, thereby decreasing the risk of lower exposures in 
heavier patients.18,19
Higher doses of intravenous reslizumab have previously 
been shown to be associated with larger reductions in 
blood eosinophil counts and greater improvements in 
lung function (FEV1) and patient-reported outcomes,11 
compared with lower doses, supporting an exposure–
response relationship for reslizumab. This relationship 
was confirmed in the exposure–response analysis in 
study 1. The exposures achieved in study 1 with fixed-dose 
subcutaneous reslizumab were sufficient for improve-
ments in mean change from baseline in FEV1, but 
exposures higher than those observed with 110 mg are 
presumably required to reach maximal efficacy in terms of 
reducing the exacerbation risk in most patients. Our 
exposure–response analysis for reductions in the annual 
frequency of clinical asthma exacerbations in study 1 
showed an inverse relationship between exposure and 
exacerbation rate, with higher reslizumab exposures 
associated with lower exacerbation frequencies, suggesting 
the need for higher exposures to reach the concentration 
threshold required for maximal efficacy in the greatest 
proportion of patients. Similar results were observed in the 
exposure–response analysis of time to first clinical asthma 
exacerbation.
The effect of body weight on other treatments targeting 
the IL5 pathway has also been assessed. Body weight 
was identified as a relevant covariate influencing 
the pharmacokinetics of other anti-IL5 drugs.20,21 The 
exposure–response relationship and the effect of patient 
body weight on the efficacy of treatments targeting the 
IL5 pathway should be explored in more detail in further 
studies or analyses.
In study 1, annual rates of clinical asthma exacerbations 
during the treatment period were low with placebo 
compared with the baseline period (12 months before 
screening). This finding might be partly due to treatment 
non-adherence or suboptimal treatment before study 
enrolment, which minimised treatment differences in 
the study. Additionally, results from our prespecified 
subgroup analyses in study 1 suggested that heterogeneity 
in regional exacerbation rates during the treatment 
period might have contributed to the size of the treatment 
effect: patients enrolled from eastern Europe and, to a 
lesser extent, South America, had a very low frequency of 
exacerbations during the treatment period, irrespective 
of treatment group. Similar findings were made in other 
studies of biologic drugs for the treatment of severe 
asthma,17 without clear cause, and additional studies are 
warranted. Regardless of these regional differences, 
the relationship between body weight and reslizumab 
concentrations and the consequent exposure–response 
relationship were evident across the study population.
Despite the evidence for pharmacological activity with 
reslizumab in study 1, we found no significant treatment 
differences in efficacy outcomes in study 2, which was 
designed to investigate the oral corticosteroid-sparing 
effect of reslizumab in patients who had more severe 
asthma at baseline than did participants in study 1. 
Patients in study 2 were older, had a longer duration of 
asthma, worse lung function, and higher body weight 
than did those in study 1. Because fewer low-weight 
patients were included in study 2 compared with study 1, 
reslizumab exposures were lower in study 2. Our findings 
suggest that the systemic drug concentrations obtained 
with reslizumab 110 mg were not sufficient to show a 
quantifiable difference between treatment groups in 
corticosteroid dose reduction in most patients with severe 
oral corticosteroid-dependent asthma; as in study 1, higher 
exposures are probably required to achieve clinically 
relevant improvements in efficacy outcomes. These 
results concur with previous studies of the relationship 
between exposures and clinical efficacy outcomes for anti-
IL5 therapies in patients with severe oral corticosteroid-
dependent asthma.22 Results from study 2 were not pooled 
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with study 1 in the exposure–response analysis because of 
the differences in study design.
Reslizumab rapidly decreased blood eosinophil counts 
to a low but detectable concentration by the first visit 
in both studies. Decreases in blood eosinophil counts 
were not sufficient for clear improvements in clinical 
outcomes in either study. Although baseline blood 
eosinophil levels of 400 cells per µL or more are an 
adequate biomarker to indicate baseline eosinophilic 
airway inflammation, reduction in blood eosinophils with 
treatment is a surrogate biomarker, which might not fully 
reflect changes in eosinophilic airway inflam mation. Blood 
eosinophil counts also decreased in the placebo groups, 
but to a much smaller extent. This post-baseline decrease 
in the placebo group might be due to regression to the 
mean based on the definition used for baseline eosinophil 
counts, which were assessed as the highest pre-dose value 
during screening and run-in. The decrease in peripheral 
blood eosinophils in placebo-treated patients might also 
indicate better adherence to inhaled corticosteroids during 
the study compared with pre-study adherence.23
Subcutaneous reslizumab once every 4 weeks was 
generally well tolerated. We found few treatment-related 
AEs and discontinuations due to AEs. The AEs reported 
during the studies were consistent with the expected 
profiles for patients with uncontrolled severe asthma in 
study 1 and with severe oral corticosteroid-dependent 
asthma in study 2, and with previous experience with 
intravenous reslizumab.9,11 Few patients developed anti-
drug anti bodies, which were generally transient, low titre, 
non-neutralising, and not related to efficacy and safety.
These studies had several limitations. The studies 
were adequately powered, so we believe that the negative 
findings for the primary endpoints in the overall 
populations of both studies are meaningful; however, 
patient numbers for the subgroups were low, which 
limited the statistical power to detect subgroups that 
might have benefited from reslizumab. Because of 
multiple comparisons, a multiple testing procedure was 
implemented, resulting in only descriptive comparisons 
for secondary endpoints given that the p value was greater 
than 0·05 for the comparison of the primary endpoint in 
both studies. The inclusion of patients with a blood 
eosinophil count between 300 cells per µL and less than 
400 cells per µL probably weakened our ability to show 
a treatment effect in either study, because a blood 
eosinophil count of 400 cells per µL or more appears to be 
a better indicator of eosinophil-driven asthma responsive 
to anti-IL5 therapy. A low asthma exacerbation rate in 
the placebo group also decreased our ability to show a 
treatment effect for asthma exacerbation reduction. On 
the basis of our post-hoc exposure–response analyses, 
doses of subcutaneous reslizumab higher than 110 mg 
once every 4 weeks will probably be required to achieve 
more robust improvements in efficacy outcome measures. 
Additionally, no long-term safety data beyond 52 weeks for 
subcutaneous reslizumab are available.
In conclusion, reslizumab given as a fixed-dose (110 mg) 
subcutaneous injection was not effective in reducing 
exacerbation rates in patients with uncontrolled asthma 
and an increased blood eosinophil count (≥300 cells/µL), 
or in reducing the daily maintenance oral corticosteroid 
dose in patients with oral corticosteroid-dependent severe 
eosinophilic asthma. Subcutaneous reslizumab showed 
evidence of pharmacological activity in study 1, in terms 
of clinically significant improvements in lung function at 
2 weeks, which were sustained until week 52, and 
clinically important improvements in exacerbation 
frequency in the subgroup of patients with high blood 
eosinophil counts (≥400 cells/µL). However, the mag-
nitude of effect of fixed-dose subcutaneous reslizumab on 
rates of clinical asthma exacerbations was lower than the 
50–59% reduction observed with the higher reslizumab 
exposures associated with weight-based dosing of 
intravenous reslizumab. Reslizumab was generally well 
tolerated and no new safety concerns were detected. 
Exposure-response analyses indicate that to achieve the 
magnitude of effect on clinical asthma exacerbations 
observed with intra venous reslizumab 3 mg/kg, systemic 
reslizumab concentrations higher than those achieved 
with subcutaneous 110 mg are required. The use of 
higher, weight-based doses of subcutaneous reslizumab 
should be assessed in future studies.
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